BioMed Research International / 2017 / Article / Tab 4

Review Article

New Insights into the Epigenetics of Hepatocellular Carcinoma

Table 4

Drugs that target epigenetic modifications in HCC [3].

Epigenetic modificationDrugsResultsRef.

Histone deacetylation that targets histone deacetylaseSuberoylanilide hydroxamic acidTNF-related apoptosis-inducing ligand-induced apoptosis.[100]
BelinostatTumor stabilization was observed in nonresectable advanced HCC.[101]
BelinostatInduction of apoptosis and inhibition of cell growth occurred.[102]

DNA methylation that targets DNA methyltransferases5-Aza-2′-deoxycytidineInhibition of telomerase activity and reactivation of c-Myc and p16 were observed.[103]
ZebularineInduction of apoptosis and inhibition of cell proliferation were observed in HepG2 cell line.[104]
ZebularineTumor growth was inhibited in xenograft models. Genes involved in apoptosis, cell cycle, and tumor suppression were demethylated in KMHC and Huh-7 cell lines.[105]

Combined epigenetic modifications that target tyrosine kinase inhibitors and histone deacetylase inhibitorsPanobinostat + sorafenibCombined activity of these two drugs induced apoptosis, increased survival, and decreased tumor density and tumor volume.[106]

You are browsing a BETA version of Click here to switch back to the original design.